Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SARS and Avian Flu -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2717)	10/15/2005 1:15:54 PM
From: Elroy Jetson	Read Replies (2) \| Respond to of 4232

Your perception of Passive IGG therapy has been flatly contradicted by the failure of trials for many previous viral diseases. Not one viral IGG product that I'm aware of has ever led to an approved drug, in spite of decades of trials. Do you know of any? Post-exposure IGG is used to help prevent Hep-A, but not treat it. Are you actually suggesting "preventative" injections of IGG for the world's population from the hundred or so bird flu survivors? You were misinformed when someone told you that monoclonal antibodies are not used to treat sepsis. Go to Medline, there is a wealth of information. Unlike Passive IGG therapy for viral infections, monoclonal antibody treatment for sepsis actually works. jama.ama-assn.org www-ermm.cbcu.cam.ac.uk pulmonaryreviews.com general-medicine.jwatch.org .